Efficacy and safety of mitapivat in pediatric patients with pyruvate kinase deficiency who are not regularly transfused: Results from the Phase 3, global, randomized, double-blind, placebo-controlled ACTIVATE-Kids trial
Publication
, Conference
Chonat, S; Grace, R; Dickerson, K; Andres, O; Bartels, M; Beynon, V; Despotovic, J; Glader, B; Huguenin, Y; Kwiatkowski, J; Laflam, E; Yin, O ...
Published in: Blood
November 3, 2025
Duke Scholars
Published In
Blood
DOI
EISSN
1528-0020
ISSN
0006-4971
Publication Date
November 3, 2025
Volume
146
Issue
Supplement 1
Start / End Page
4654 / 4654
Publisher
American Society of Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
Citation
APA
Chicago
ICMJE
MLA
NLM
Chonat, S., Grace, R., Dickerson, K., Andres, O., Bartels, M., Beynon, V., … Sevilla, J. (2025). Efficacy and safety of mitapivat in pediatric patients with pyruvate kinase deficiency who are not regularly transfused: Results from the Phase 3, global, randomized, double-blind, placebo-controlled ACTIVATE-Kids trial. In Blood (Vol. 146, pp. 4654–4654). American Society of Hematology. https://doi.org/10.1182/blood-2025-4654
Chonat, Satheesh, Rachael Grace, Kathryn Dickerson, Oliver Andres, Marije Bartels, Vanessa Beynon, Jenny Despotovic, et al. “Efficacy and safety of mitapivat in pediatric patients with pyruvate kinase deficiency who are not regularly transfused: Results from the Phase 3, global, randomized, double-blind, placebo-controlled ACTIVATE-Kids trial.” In Blood, 146:4654–4654. American Society of Hematology, 2025. https://doi.org/10.1182/blood-2025-4654.
Chonat S, Grace R, Dickerson K, Andres O, Bartels M, Beynon V, et al. Efficacy and safety of mitapivat in pediatric patients with pyruvate kinase deficiency who are not regularly transfused: Results from the Phase 3, global, randomized, double-blind, placebo-controlled ACTIVATE-Kids trial. In: Blood. American Society of Hematology; 2025. p. 4654–4654.
Chonat, Satheesh, et al. “Efficacy and safety of mitapivat in pediatric patients with pyruvate kinase deficiency who are not regularly transfused: Results from the Phase 3, global, randomized, double-blind, placebo-controlled ACTIVATE-Kids trial.” Blood, vol. 146, no. Supplement 1, American Society of Hematology, 2025, pp. 4654–4654. Crossref, doi:10.1182/blood-2025-4654.
Chonat S, Grace R, Dickerson K, Andres O, Bartels M, Beynon V, Despotovic J, Glader B, Huguenin Y, Kwiatkowski J, Laflam E, Rivadeneyra L, McGee B, Yin O, Murciano Carrillo T, Pastore Y, Rothman J, Tyler P, Xu E, Renella R, Sevilla J. Efficacy and safety of mitapivat in pediatric patients with pyruvate kinase deficiency who are not regularly transfused: Results from the Phase 3, global, randomized, double-blind, placebo-controlled ACTIVATE-Kids trial. Blood. American Society of Hematology; 2025. p. 4654–4654.
Published In
Blood
DOI
EISSN
1528-0020
ISSN
0006-4971
Publication Date
November 3, 2025
Volume
146
Issue
Supplement 1
Start / End Page
4654 / 4654
Publisher
American Society of Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology